PD-1 Antibody definition

PD-1 Antibody means an Antibody that Interacts with PD-1 that is Controlled by Agenus or, subject to Section 12.3(b)(ii), any of its Affiliates as of the Effective Date or arises out of an internal discovery project conducted by Agenus or, subject to Section 12.3(b)(ii) any of its Affiliates during the period beginning on the Effective Date and ending [**] thereafter.
Sample 1Sample 2Sample 3
PD-1 Antibody means an antibody binding to PD-1.
Sample 1Sample 2Sample 3
PD-1 Antibody means any a monospecific monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with the XX-0 xxxxxxx XX-X0 and PD-L2.
Sample 1

Examples of PD-1 Antibody in a sentence

  • Temperature distribution of the OC for different power levels is shown in Figure 5.

  • Enter into Cooperation Agreement on Combination of PD-1 Antibody JS001 with JAB-3068 (關於PD-1抗體JS001與JAB-3068聯合用藥的合作協議) with a related party Jacobio Pharmaceuticals Co., Ltd.* (北京加科思新藥研發有限公司).

  • This further endorsed our commercial manufacturing capabilities and cemented WuXi Biologics as the company with the first FDA-approved cGMP production facility, to commercially manufacture biologics in China.• In August, the Company together with our partner Harbin Gloria Pharmaceuticals Co., Ltd., licensed the Fully Human PD-1 Antibody (GLS-010) to Arcus Biosciences, Inc.

  • Peng S, Ferrall L, Gaillard S, Wang C, Chi WY, Huang CH, Roden RBS, Wu TC, Chang YN, Hung CF: Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.

  • Safety, Activity, and Immune Correlates of Anti– PD-1 Antibody in Cancer.

  • See Bristol-Myers Squibb, Bristol-Myers Squibb and Ono Pharmaceutical Company Enter Settlement and License Agreement with Merck to Resolve PD-1 Antibody Patent Litigation (Jan.

  • PD-1 Antibody Formulation Innovent Suzhou PCT094122PCT/CN2016/ 08/09/2016 8.

  • The Humanized Anti PD-1 Antibody, CT-011, Increases Specific CD4+ Effector/Memory and Memory T Lymphocytes in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Following Autologous Stem Cell Transplantation (AuSCT).

  • Part B will enroll patients who have or are failing pembrolizumab at least 12 weeks after starting PD-1 Antibody alone or in combination.

  • PD-1 Antibody versus ICC as Second or Third-Line Treatment of Metastatic Melanoma Nivolumab, 3mg/kg Q2wks We have recently shown that the non-receptor IL-2 inducible tyrosine kinase (ITK) is highly expressed in metastatic cutaneous melanoma and that its pharmacologic inhibition using the highly specific ITK inhibitor, BI10N, delays tumor growth in vitro as well as in various melanoma mouse models (Carson et al., 2015).


More Definitions of PD-1 Antibody

PD-1 Antibody means any a monospecific monoclonal antibody that binds to the PD- 1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.
Sample 1

Related to PD-1 Antibody

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

  • Licensed Compound means (a) 3,4-Diaminopyridine, the chemical structure of which is set forth on Exhibit B-2; and (b) any derivatives, isomers, metabolites, prodrugs, acid forms, base forms, salt forms, or modified versions of such compound in (a).

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Antigen means a substance recognized by the body as being foreign; it results in the production of specific antibodies directed against it.

  • Opioid antidote means any drug, regardless of dosage amount or method of administration, which has been approved by the United States Food and Drug Administration (FDA) for the treatment of an opioid overdose. “Opioid antidote” includes, but is not limited to, naloxone hydrochloride, in any dosage amount, which is administered through nasal spray or any other FDA-approved means or methods.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Product Candidate means each of MYO-101, MYO-102, MYO-103, MYO-201 and MYO-301, as defined on Exhibit B, in each case in any form or formulation.

  • Diagnostic Product means In Vitro Diagnostics, In Vivo Diagnostic Agents and any product used for Diagnosis.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • Reference biological product means the single biological product licensed pursuant to 42 U.S.C.

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • Biological product means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

  • Compounds means a small molecule HMT inhibitor.

  • Biosimilar Product means, with respect to a Licensed Product in any country, any biosimilar product sold by a Third Party not authorized by or on behalf of Celgene, its Affiliates or Sublicensees, (a) that is a biosimilar biological product, as defined in 21 USC 379j-51 (or any successor or replacement thereof), a similar biological medicinal product, as defined in Annex I to Directive 2001/83/EC (or any successor or replacement thereof), or any similar biosimilar or generic product under the Laws of any country or jurisdiction, or (b) regarding which Regulatory Approval is obtained by referencing Regulatory Data of such Licensed Product.

  • Anti-Static Product means a product that is labeled to eliminate, prevent, or inhibit the accumulation of static electricity. “Anti-Static Product” does not include “Electronic Cleaner,” “Floor Polish or Wax,” “Floor Coating,” and products that meet the definition of “Aerosol Coating Product” or “Architectural Coating.”

  • Nicotine product means a product that contains nicotine and is not any of the following:

  • Opioid antagonist means a drug that binds to opioid

  • Biomarker means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.

  • Hemp product means the same as that term is defined in § 3.2-4112.

  • Combination Product means (a) a product containing a Licensed Product together with one or more other active ingredients that have independent biologic or chemical activity when present alone that are sold as a single unit, or (b) a Licensed Product together with one or more products, devices, pieces of equipment or components thereof, that are sold as a single package at a single price.

  • Therapeutically equivalent drug products means drug products that contain the same active ingredients and are identical in strength or concentration, dosage form, and route of administration and that are classified as being therapeutically equivalent by the U.S. Food and Drug Administration pursuant to the definition of "therapeutically equivalent drug products" set forth in the most recent edition of the Approved Drug Products with Therapeutic Equivalence Evaluations, otherwise known as the "Orange Book."